Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...

Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular ...

Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...

The electrophysiologic mechanism may be due to either enhanced automaticity or triggered activity. In contrast to the paroxysmal variety, the nonparoxysmal type develops gradually and disappears ...

Please provide your email address to receive an email when new articles are posted on . High-risk patients getting catheter ablation for ventricular tachycardia did not benefit from a mechanical ...

Ablation, a procedure to treat abnormal electrical short circuits caused by a heart attack and is usually reserved for patients who do not improve with medication, may be a better first-line treatment ...

Untreated or unmanaged, SVT can lead to other possibly fatal heart abnormalities. Patients are advised to practice a cardiac-friendly diet and lifestyle (low sodium, little to no caffeine or alcohol, ...

We demonstrated a significant rise in CRP at a median of 49 days after AF ablation. Although the subsequent decline in CRP observed at second follow-up (a median of 179 days after ablation) was not ...

SAN FRANCISCO -- Noninvasive stereotactic radiotherapy (RT) for refractory ventricular tachycardia (VT) achieved outcomes similar to catheter ablation with substantially fewer serious adverse events ...

Initial strategy of catheter ablation leads to lower risk for composite primary end point versus antiarrhythmic drug therapy. (HealthDay News) — An initial strategy of catheter ablation leads to a ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermedical ®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an ...